ABEO Abeona Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ABEO

Price (delayed)

$4.55

Market cap

$112.72M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.42

Enterprise value

$113.36M

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. Abeona's clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis ...

Highlights
Abeona Therapeutics's equity has surged by 136% QoQ and by 43% YoY
ABEO's EPS has soared by 98% year-on-year and by 55% since the previous quarter
Abeona Therapeutics's net income has surged by 51% YoY but it has decreased by 16% QoQ
The company's gross profit fell by 18% YoY
The revenue is down by 18% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://abeonatherapeutics.com
Peers: MRK

Key stats

What are the main financial stats of ABEO
Market
Shares outstanding
24.77M
Market cap
$112.72M
Enterprise value
$113.36M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.11
Price to sales (P/S)
31.62
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
31.77
Earnings
Revenue
$3.57M
EBIT
-$38.24M
EBITDA
-$34.75M
Free cash flow
-$41.75M
Per share
EPS
-$0.42
Free cash flow per share
-$1.68
Book value per share
$0.89
Revenue per share
$0.14
TBVPS
$2.67
Balance sheet
Total assets
$66.09M
Total liabilities
$44.05M
Debt
$5.69M
Equity
$22.04M
Working capital
$48.85M
Liquidity
Debt to equity
0.26
Current ratio
6.81
Quick ratio
6.69
Net debt/EBITDA
-0.02
Margins
EBITDA margin
-973.9%
Gross margin
100%
Net margin
-1,085.3%
Operating margin
-1,265.6%
Efficiency
Return on assets
-65.3%
Return on equity
-201.5%
Return on invested capital
-76.6%
Return on capital employed
-66.3%
Return on sales
-1,071.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ABEO stock price

How has the Abeona Therapeutics stock price performed over time
Intraday
-0.22%
1 week
-7.14%
1 month
2.94%
1 year
28.9%
YTD
47.73%
QTD
8.08%

Financial performance

How have Abeona Therapeutics's revenue and profit performed over time
Revenue
$3.57M
Gross profit
$3.57M
Operating income
-$45.16M
Net income
-$38.72M
Gross margin
100%
Net margin
-1,085.3%
Abeona Therapeutics's net income has surged by 51% YoY but it has decreased by 16% QoQ
The operating income has increased by 46% YoY but it has decreased by 4.5% from the previous quarter
Abeona Therapeutics's net margin has increased by 40% YoY but it has decreased by 16% QoQ
ABEO's operating margin is up by 35% YoY but it is down by 4.4% QoQ

Growth

What is Abeona Therapeutics's growth rate over time

Valuation

What is Abeona Therapeutics stock price valuation
P/E
N/A
P/B
5.11
P/S
31.62
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
31.77
ABEO's EPS has soared by 98% year-on-year and by 55% since the previous quarter
Abeona Therapeutics's equity has surged by 136% QoQ and by 43% YoY
The price to book (P/B) is 132% higher than the 5-year quarterly average of 2.2 and 16% higher than the last 4 quarters average of 4.4
ABEO's P/S is 36% below its 5-year quarterly average of 49.5 but 14% above its last 4 quarters average of 27.8
The revenue is down by 18% year-on-year

Efficiency

How efficient is Abeona Therapeutics business performance
The company's return on invested capital has surged by 74% YoY and by 3.8% QoQ
The company's return on assets has surged by 57% YoY but it fell by 2.8% QoQ
ABEO's ROS is up by 41% year-on-year but it is down by 17% since the previous quarter
Abeona Therapeutics's return on equity has increased by 34% YoY but it has decreased by 6% QoQ

Dividends

What is ABEO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ABEO.

Financial health

How did Abeona Therapeutics financials performed over time
The company's total assets is 50% higher than its total liabilities
ABEO's total liabilities has soared by 89% YoY
The company's total assets has surged by 70% YoY and by 23% QoQ
Abeona Therapeutics's debt is 74% lower than its equity
Abeona Therapeutics's equity has surged by 136% QoQ and by 43% YoY
Abeona Therapeutics's debt to equity has shrunk by 59% QoQ and by 52% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.